Abstract
Objective
In this study, quality of life and psychiatric comorbid disorders were investigated in patients with cervical dystonia and their spouses and we also investigated the effect of botulinum toxin (BTX) treatment on these parameters.
Material and method
Thirty patients with cervical dystonia (CD) on BTX treatment and their spouses (n = 30) were included. Beck Depression Scale (BDS), State-Trait Anxiety Inventory I and II (STAI-I, STAI-II), Hospital Anxiety Scale (HAS), Hospital Depression Scale (HDS) for psychiatric comorbid disease assessment, Toronto Western Spasmodic Torticollis Scale (TWSTRS) for disease activity assessment, and Craniocervical Dystonia Questionnaire (CDQ-24), Cervical Dystonia Impact Profile (CDIP-58), and Short Form 36 (SF-36) questionnaires for quality of life assessment were used. BDS, STAI-I and STAI-II, HAS, HDS, and SF-36 scales were also obtained from the spouses. The same tests were applied both before and 8 weeks after the BTX treatment.
Conclusion
In our study, an increase in psychiatric comorbid disorders such as depression and anxiety was observed and the quality of life was adversely affected in all areas in patients. In the spouses of the patients, the rates of psychiatric comorbid disorders such as depression and anxiety were found to be increased when compared to healthy subjects while vitality, mental health, and general health perception were found to be negatively affected.
Patients showed improvements in anxiety level, disease activity, and overall quality of life scales after BTX treatment.
Similar content being viewed by others
References
Zurowski M, McDonald WM, Fox S, Marsh L (2013) Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord 28. https://doi.org/10.1002/mds.25501
Fitzpatrick R (1992) “Quality of Life Measures in Health Care”, Applications and Issues in Assessement. BMJ 305:1074–1077
Page D, Butler A, Jahanshahi M (2007) Quality of life in focal, segmental and generalized dystonia. Mov Disord 23(3):341–347
Queiroz MR, Chien HF, Barbosa ER (2011) Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital. Arq Neuropsiquiatr 69:900–904
Ben-Shlomo Y, Camfield L, Warner T, on behalf of the ESDE collaborative group (2002) What are the determinants of quality of life in people with cervical dystonia. J Neurol Neurosurg Psychiatry 72:608–614
Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161–164
Stamelou M, Edwards MJ, Hallett M, Bathia KP (2012) The non -motor syndrome of primary dystonıyia: clinical and pathophysiological implications. Brain 135:1668–1681
Akın YA, Akbostanci C, Mercan N, Aksun Z, Sorgun M (2012) Retrospective evaluation of 118 cervical dystonic cases treated with botulinum toxin Turk. J Neurol 18(3):104–107
Jog M, Chouinard S, Hobson D et al (2011) Causes for treatment delays in dystonia and Hemifacial spasm: a Canadian SurveyCan. J Neurol Sci 38:704–711
Tomic S, Petkovic I, Pucic T, Resan B et al (2016) Cervical dystonia and quality of life. Acta Neurol Belg 116:589–592
Slawek J, Friedman A, Potulska A et al (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type a injections. Functl Neurol 22:95–100
Moraru E, Schnider P, Wimmer A, Wenzel T, Birner P, Griengl H et al (2002) Relation between depression and anxiety in dystonic patients: implications for clinical management. Depress Anxiety 16:100–103
Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W (2002) The Austrian botulinum toxin and dystonia study group. The impact of blepharospasm and cervical dystonia on health related quality of life and depression. J Neurol 249:842–846
Fabbri M, Superbo M, Defazio G, Scaglione CLM, Antelmi E, Basini G, Nassetti S, Pizza F, Plasmati R, Liguori R (2014) Quality of life in patients with craniocervical dystonia: Italian validation of the “cervical dystonia impact profile(CDIP-58)” and the “Craniocervical dystonia questionnaire (CDQ-24) ”. Neurol Sci 35:1053–1058
Lim VK (2007) Health related quality of life in patients with dystonia and tehir caregivers in new Zeland and Australia. Mov Disord 22(7):998–1003
Wollmer MA, Boer C, Kalak N et al (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 46:574–581
Kocaman G, Baslo MH, Hanağası H, Parman Y. İdyopatik servikal distonili hastalarda botulinum toksini uygulanmasından önce ve sonra kas aktivasyon paterninde görülen değişimlerin incelenmesi Nöropsikiyatri Arflivi 2009; 46: 39–43
Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C et al (2010) Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord 25:459–465
Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J (2013) An open label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin a (Dysport). BMJ Open 3:e0011853. https://doi.org/10.1136/bmjopen-2012-001853
Jen MH, Kurth H (2014) Assessing the burden of illness from cervical dystonia using the Toronto Western spasmodic torticollis rating scale scores and health utility: a meta- analysis of baseline patient-level clinical trial data. J Med Econ 17(11):803–809
Funding
This research did not receive any grants or funding from any funding agencies. The authors have no funding to report.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ceylan, D., Erer, S., Zarifoğlu, M. et al. Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. Neurol Sci 40, 725–731 (2019). https://doi.org/10.1007/s10072-019-3719-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-019-3719-9